Incannex appoints qps to advance cannquit-n™ (nicotine), cannquit-o™ (opioid) and renecann™ products in the usa and eu

Melbourne, australia, april 14, 2023 (globe newswire) -- incannex healthcare ltd (nasdaq: ixhl) (asx: ihl) (‘incannex' or ‘the company') a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet medical needs, is pleased to announce that is has appointed quest pharmaceutical services (‘qps') to provide regulatory advice and manage clinical trials for the development of cannquit™ and renecann™ products for addiction and immune-disordered skin diseases.
IXHL Ratings Summary
IXHL Quant Ranking